Dyne Therapeutics (NASDAQ:DYN) CFO Erick Lucera Sells 2,362 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Erick Lucera also recently made the following trade(s):

• On Wednesday, May 13th, Erick Lucera sold 1,448 shares of Dyne Therapeutics stock. The shares were sold at an average price of $18.36, for a total value of $26,585.28.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded up $0.33 during midday trading on Friday, hitting $20.94. The company had a trading volume of 5,436,037 shares, compared to its average volume of 2,013,259. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The stock has a market cap of $3.46 billion, a price-to-earnings ratio of -6.50 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The business’s 50-day simple moving average is $18.43 and its 200-day simple moving average is $18.09.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the business posted ($1.05) EPS. On average, research analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning grew its holdings in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after purchasing an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics in the 1st quarter valued at about $26,000. Caxton Associates LLP raised its holdings in Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its position in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.